Devyser, a Sweden-based provider of diagnostic kits and solutions for DNA testing, has launched two new products, Devyser LynchFAP and Devyser BRCA PALB2.

The test kits are designed to provide targeted, and confident analysis of genes linked to elevated cancer risk, such as Lynch syndrome, and breast and ovarian cancers.

The Devyser LynchFAP is a comprehensive solution for the analysis of PMS2 and nine other genes related to hereditary colorectal cancer syndromes.

It is designed to overcome the localisation of genetic variants to PMS2 and its pseudogene PMS2CL, one of the greatest challenges for Lynch syndrome genetic testing.

The test kit, together with simple next-generation sequencing (NGS) workflow, and dedicated software will address complex genetics with an intuitive and easy-to-use solution.

Devyser LynchFAP is the first commercial library prep kit that allows specific analysis of the PMS2 gene, said the Swedish diagnostic technology company.

Devyser CEO Fredrik Alpsten said: “We are delighted to introduce Devyser LynchFAP and Devyser BRCA PALB2 to the market. These genetic testing solutions represent a significant advancement in our hereditary cancer offering.

“By understanding mutations associated with increased cancer risks, our ambition is to enable more personalized care and preventive measures, ultimately saving lives.”

Devyser BRCA PALB2 is designed to provide a targeted solution with simple and commercially available workflow for crucial genetic information related to breast and ovarian cancer.

The test kit facilitates sequencing of genetic variants in BRCA1, BRCA2, and PALB2, the three most significant genes increasing breast cancer risk.

Its simplified workflow enables rapid laboratory implementation and streamlines the analysis of genetic variants in DNA from human blood and tumour tissue, into a single solution.

Colorectal cancer is one of the most common cancer types in the world, where 10-20% of cases are due to hereditary cancer syndromes such as Lynch syndrome.

The incidence of a hereditary cancer syndrome significantly increases an individual’s risk of developing colorectal cancer, among multiple other cancer types, said Devyser.

In April this year, Devyser has signed an exclusive collaboration and distribution agreement with US-based medical equipment maker Thermo Fisher Scientific.